Galectin-9 Induces Mitochondria-Mediated Apoptosis of Esophageal Cancer In Vitro and In Vivo in a Xenograft Mouse Model

miR-582-5p inhibits invasion and migration of salivary adenoid cystic carcinoma cells by targeting FOXC1

(2017) Wei-Wei Wang et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Effects of galectin-9 on apoptosis, cell cycle and autophagy in human esophageal adenocarcinoma cells

(2017) Emiko Akashi et al.   ONCOLOGY REPORTS

A systematic review and network meta-analysis of neoadjuvant therapy combined with surgery for patients with resectable esophageal squamous cell carcinoma

(2017) Yuanwei Huang et al.   International Journal of Surgery

Nanotechnology inspired tools for mitochondrial dysfunction related diseases

(2016) Ru Wen et al.   ADVANCED DRUG DELIVERY REVIEWS

Galectin-9: An anticancer molecule for gallbladder carcinoma

(2016) TOMOKO TADOKORO et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Chemoradiotherapy for esophageal squamous cell cancer

(2016) Yusuke Sasaki et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Galectin expression in cancer diagnosis and prognosis: A systematic review

(2015) Victor L. Thijssen et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Global Cancer Incidence and Mortality Rates and Trends--An Update

(2015) L. A. Torre et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Upregulation of miR-582-5p inhibits cell proliferation, cell cycle progression and invasion by targeting Rab27a in human colorectal carcinoma

(2015) X Zhang et al.   CANCER GENE THERAPY

Galectin-9 as an important marker in the differential diagnosis between oral squamous cell carcinoma, oral leukoplakia and oral lichen planus

(2015) Janusa Maria Muniz et al.   IMMUNOBIOLOGY

Galectin-9 suppresses the growth of hepatocellular carcinoma via apoptosis in vitro and in vivo

(2015) KOJI FUJITA et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences

(2015) K. Wang et al.   ONCOLOGIST

Galectin-9 suppresses cholangiocarcinoma cell proliferation by inducing apoptosis but not cell cycle arrest

(2015) KIYOYUKI KOBAYASHI et al.   ONCOLOGY REPORTS

miR-582-5p inhibits proliferation of hepatocellular carcinoma by targeting CDK1 and AKT3

(2015) Yi Zhang et al.   TUMOR BIOLOGY

Changed Expression of E-cadherin and Galectin-9 in Oral Squamous Cell Carcinomas but Lack of Potential as Prognostic Markers

(2014) Siew Wui Chan et al.   Asian Pacific Journal of Cancer Prevention

Dual Role of JNK1-mediated phosphorylation of Bcl-2 in autophagy and apoptosis regulation

(2014) Yongjie Wei et al.   Autophagy

miRNA in hepatocellular carcinoma

(2014) Asahiro Morishita et al.   HEPATOLOGY RESEARCH

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

(2014) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

Galectin-9 controls the therapeutic activity of 4-1BB–targeting antibodies

(2014) Shravan Madireddi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Galectin-9 Increases Tim-3+ Dendritic Cells and CD8+ T Cells and Enhances Antitumor Immunity via Galectin-9-Tim-3 Interactions

(2014) K. Nagahara et al.   JOURNAL OF IMMUNOLOGY

Regulation of osteoclastogenesis through Tim-3: possible involvement of the Tim-3/galectin-9 system in the modulation of inflammatory bone destruction

(2014) Kanako Moriyama et al.   LABORATORY INVESTIGATION

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

(2014) Hansjochen Wilke et al.   LANCET ONCOLOGY

Galectin fingerprinting in naso-sinusal diseases

(2014) ANAËLLE DURAY et al.   ONCOLOGY REPORTS

Correction: A Crucial Role for Kupffer Cell-Derived Galectin-9 in Regulation of T Cell Immunity in Hepatitis C Infection

(2014) John A. Mengshol et al.   PLoS One

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

(2013) Charles S Fuchs et al.   LANCET

Therapeutic Effects of MicroRNA-582-5p and -3p on the Inhibition of Bladder Cancer Progression

(2013) Keita Uchino et al.   MOLECULAR THERAPY

The Glycan-Binding Protein Galectin-9 Has Direct Apoptotic Activity toward Melanoma Cells

(2012) Valerie R. Wiersma et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

(2010) Yung-Jue Bang et al.   LANCET

Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways

(2010) T Kobayashi et al.   LEUKEMIA

Targeting Activating Transcription Factor 3 by Galectin-9 Induces Apoptosis and Overcomes Various Types of Treatment Resistance in Chronic Myelogenous Leukemia

(2010) J. Kuroda et al.   MOLECULAR CANCER RESEARCH

Galectin-9 Is a High Affinity IgE-binding Lectin with Anti-allergic Effect by Blocking IgE-Antigen Complex Formation

(2009) Toshiro Niki et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis

(2008) Masako Seki et al.   CLINICAL IMMUNOLOGY

Galectin-9 expression links to malignant potential of cervical squamous cell carcinoma

(2008) Meiyan Liang et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Incidence of Adenocarcinoma of the Esophagus Among White Americans by Sex, Stage, and Age

(2008) L. M. Brown et al.   JNCI-Journal of the National Cancer Institute

JNK signaling in apoptosis

(2008) D N Dhanasekaran et al.   ONCOGENE